A novel scoring system based on common laboratory tests predicts the efficacy of TNF-inhibitor and IL-6 targeted therapy in patients with rheumatoid arthritis: a retrospective, multicenter observational study

Table 1 Background data on the original 98 patients from Iizuka hospital and on an additional 228 patients from five other hospitals

	Patients from Iizuka Hospital, whose data were used to develop the scoring system (n = 98)				Patients from five other hospitals, whose data were used for the validation study (n = 228)
	TCZ group	TNF-i group		p value	TCZ group	TNF-i group		p value
Number of patients	27	71			129	99
		IFX	25			IFX	25
		ADA	10			ADA	26
		ETN	36			ETN	31
						GLM	13
						CZP	4
Female, n (%)	24 (88.9%)	59 (83.1%)		0.74	111 (86.1%)	75 (75.8%)		0.05
Age, years (SD)	60.3 (13.4)	60.7 (14.1)		0.76	58.5 (14.0)	63.0 (13.3)		0.02
TJC (SD)	10.5 (8.5)	7.9 (7.1)		0.20	10.4 (8.3)	6.9 (6.3)		0.0019
SJC (SD)	6.4 (5.3)	5.2 (4.1)		0.36	5.3 (4.8)	6.3 (4.8)		0.06
Patient VAS, mm (SD)	53.6 (29.6)	57.3 (28.9)		0.98	47.7 (26.9)	51.3 (27.6)		0.32
ESR, mm/h (SD)	47.4 (28.6)	41.6 (28.8)		0.18	53.4 (37.5)	40.7 (28.5)		0.006
CRP, mg/dL (SD)	2.9 (3.0)	2.5 (2.4)		0.34	2.5 (3.2)	3.3 (2.8)		0.75
DAS28-ESR (SD)	5.7 (2.6)	5.2 (2.5)		0.08	5.4 (1.5)	5.0 (1.3)		0.06

Data on the original 98 patients from Iizuka hospital (2005 to 2010) were used for developing a scoring system and data on the 228 patients from Iizuka hospital (2011 to 2015) and other four hospitals were used for the validation study. Data presented are number of patients or mean unless otherwise noted. TJC tender joint count, SJC swollen joint count, VAS visual analog scale, ESR erythrocyte sedimentation rate, CRP C-reactive protein, DAS28-ESR disease activity score in 28 joints calculated by using erythrocyte sedimentation rate, TCZ tocilizumab, TNF-i tumor necrosis factor inhibitor, IFX infliximab, ADA adalimumab, ETN etanercept, GLM golimumab, CZP certolizumab pegol

ISSN: 1478-6362